Glaucoma remains a major global cause of vision loss, and while therapeutic options exist, current drug delivery methods face serious limitations in both efficacy and patient adherence. This talk introduces a new investigational therapeutic solution developed to address the root challenges of glaucoma treatment, not just through better drugs, but through a fundamentally different delivery approach.

• Introduces a novel method for glaucoma treatment designed to overcome the low penetration, rapid clearance, and frequent dosing limitations of traditional eye drops and topical therapies
• Highlights the burden of poor patient adherence in glaucoma management and how long-acting solutions may reduce disease progression by eliminating the need for daily administration
• Explores how this investigational therapy, administered in a brief in-office procedure, could offer 6–12 months of intraocular pressure control, supporting a patient-friendly alternative to chronic daily treatment